

1 Endoscopic Sentinel Node Biopsy is Less Invasive and Facilitated
2 by SPECT-Fused 3D-CT Lymphography

3 Koji Yamashita¹

4 ¹ Nippon Medical School

5 *Received: 13 December 2013 Accepted: 5 January 2014 Published: 15 January 2014*

6

7 **Abstract**

8 Background: The endoscopic surgery for the breast diseases has been proven safe and
9 aesthetic and named as video-assisted breast surgery (VABS). We also applied it for sentinel
10 node (SN) biopsy. We firstly succeeded to fuse the single photon emission computed
11 tomography (SPECT) with 3D-CT mammary lymphography (LG). It can show the detailed
12 position of all SNs with or without RI uptake. Method: In 3D-CT LG, 2 ml of Iopamidol 300
13 was injected subcutaneously above the tumor and the periareola. CT scan was taken 1 minute
14 after injection to produce a 3D image of lymph ducts and nodes. In the lymphoscintigraphy,
15 99mTc phytate 74mBq was injected, and SPECT was taken after 2 hours. We fused it with
16 3D-CT LG. SN biopsy was performed endoscopically by dye and RI method.

17

18 **Index terms**— Keywords: Radioisotope, Dye, Single photon emission computed tomography (SPECT),
19 Endoscopic surgery, Sentinel lymph node biopsy, Lymphography, 3D-CT,

20 **1 I. Introduction**

21 In early breast cancer, the presence of metastasis in axillary lymph nodes (AN) is an important factor in prognosis
22 and further treatment. Sentinel node (SN) biopsy provides us valuable information about no need to dissect AN
23 for node-negative patients [1,2]. SN is defined as the first lymph node drained of lymph flow from the tumor [3,4].
24 The most commonly used methods to identify the SN are dye-staining [5,6] and radioisotope (RI) incorporation
25 [7,8]. We have reported the usefulness of multidetector-row three-dimensional computed tomography (3D-CT)
26 mammary lympho-graphy (LG) for SN biopsy [9,10,11]. It can show the detailed relations between lymph ducts
27 and lymph nodes in the axilla on the anatomical architecture [12]. And the late phase of 3D-CT LG of the breast
28 can show the axillary lymphatic architecture from SN into venous angle [13].

29 3D-CT LG can decrease the false negative study of SN biopsy with RI and/or dye-staining methods. However,
30 during surgery, we sometimes miss the exact node detected by 3D-CT LG, because the discrepancy of SN exists
31 between RI, dye, and 3D-CT LG. Up to the present, we have used the skin marking with oil pen projected by
32 the laser pointer of CT. The single stained node can be found easily, but multiple adjacent nodes cannot be
33 distinguished each other.

34 The conventional lymphoscintigraphy shows the RI-uptaken nodes, but it cannot show its exact location. Single
35 photon emission computed tomography (SPECT) show the exact location of RI-uptaken nodes in the anatomical
36 architecture. We firstly succeeded to fuse this SPECT with our 3D-CT LG. It can show the RIuptaken nodes are
37 coincided with some of the enhanced SNs by 3D-CT LG. Some SNs of 3D-CT LG included RI-uptaken nodes,
38 and dye-stained nodes, and bi-negative nodes. We can notice the location of RIuptaken nodes in the SN mapping
39 of 3D-CT LG. During surgery, RI detector probe can navigate hot node. We can find the other nodes relative to
40 these hot nodes in SN mapping of 3D-CT LG.

6 D) SURGICAL METHODS

41 2 II. Materials and Methods

42 3 a) Patients

43 From July 2002 to March 2010, 700 patients with breast disease were treated surgically by us in the Department
44 of Surgery at the Nippon Medical School of Musashikosugi Hospital and Main Hospital. We performed video-
45 assisted breast surgery (VABS) for the patients with a limited small breast cancer at surgery [14,15]. We also
46 performed SN biopsy for the patients without clinical axillary node metastasis. A SN biopsy was performed
47 for 200 patients, 160 of which involved SN biopsy using VABS and 3D-CT LG. The patient characteristics are
48 shown in Table 1. Down-staged cases treated by preoperative systemic chemotherapy (PST) are included. For
49 example, the patient with large tumor of 10 cm in diameter gained pathological complete remission (pCR) after
50 PST. These patients did not have any clinical metastasis of axillary nodes after PST.

51 4 b) 3D-CT lymphography

52 Interstitial 3D-CT LG was performed using a 16channel multidetector-row helical 3D-CT scanner (Toshiba
53 Aquilion 16; Toshiba Medical Systems Corporation, Tochigi, Japan). The patients were placed in the supine
54 position with arms positioned in the lateral abduction direction suitable for the operating position. After local
55 anesthesia by subcutaneous injection of 1% lidocaine (0.5 ml), 2 ml of contrast enhancing material iopamidol
56 (Iopamiron 300; Nihon Shering, Osaka, Japan) were injected intracutaneously into the periareolar skin and the
57 skin above the tumor. A CT image with a 3-mm slice thickness was taken 1 and 5 minutes after injection. SN was
58 identified on transaxial CT images, and their location was marked on the skin surface with an oil-painting pen
59 using a laser pointer of CT the day before the surgery. Next, 3D-CT images were reconstructed from transaxial
60 enhanced CT images, which clearly showed the lymph ducts and SN. 3D-CT LG was also performed for the
61 arm LG. 2 ml of iopamidol were injected in the upper inner arm along the medial intramuscular groove of the
62 ipsilateral arm after local anesthesia. A CT image was taken 5 minutes after injection on the same condition.

63 5 c) Spect

64 On the day before surgery, 74 MBq technetium 99m (99mTc) phytate (FUJIFILM RI Pharma Co., LTD., Tokyo,
65 Japan) in sterile saline (total volume 1 mL) was injected intradermally into two different sites of the skin above
66 the tumor and around the periareola. Lymphoscintigraphy and SPECT were performed 2 hours after injection of
67 radio colloid. If one or more focal accumulations of radioactivity (hot spots) were visualized, these were assumed
68 to be SNs. Small amount of RI markers were positioned on the jugular notch of sternum and the xiphoid process to
69 correct the fusion points. We used the image fusion software Syntegra [16] (Philips Medical Systems, Eindhoven,
70 The Netherlands) and Real INTAGE (KGT, Tokyo, Japan) to fuse SPECT data with 3D-CT LG.

71 6 d) Surgical methods

72 Previously, VABS has been described in detail [15]. The following operative procedures were performed: skin
73 incision in the axilla and/or periareola, skin flap formation via the tunnel method [17], pectoral muscle fascia
74 dissection, vertical section of the mammary gland, SN biopsy by the dye-staining method guided by preoperative
75 3D-CT LG marking, and axillary node dissection (levels 1 and 2). Radiotherapy and chemotherapy were
76 performed for malignant diseases.

77 The SN biopsy was performed by the dyestaining method using a part of the VABS technique at the beginning
78 of the operation before gland resection. In the periareolar region and over the tumor, 2 ml of 1% indocyanine
79 green were injected subcutaneously. A 1cm-long skin incision was made along wrinkles in the axilla at the position
80 marked by 3D-CT LG. A Visiport optical trocar (Covidien Japan, Tokyo, Japan) was inserted into the incision
81 after 20 minutes. The endoscopic view was observed through the Visiport with a 10-mm-diameter straight-angled
82 rigid endoscope (Olympus Optical, Tokyo, Japan), and the stained nodes were found by following the dye in the
83 lymph ducts. RI detector probe NAVIGAOR GPS system (Covidien Japan, Tokyo, Japan) was used for detecting
84 RI-uptaken nodes.

85 The lymph nodes were sampled, and metastasis was determined from fast frozen sections. To remove them,
86 we left the external tube of the Visiport and grasped the nodes by the endodissector (Johnson & Johnson
87 Company, New Brunswick, NJ, USA), then cut and shielded the surrounding lymph duct and vessels using the
88 harmonic scalpel (Johnson & Johnson Company). Axillary node dissection was performed at levels 1 and 2 with
89 bipolar scissors through the same incision, which was lengthened to 2.5 cm. The inferior pectoral nerve, long
90 thoracic nerve, second and third intercostobrachial nerves, thoracodorsal nerve, artery, and vein were observed
91 and preserved. The lateral pectoral artery was preserved for the lateral tissue flap. After surgery, SN and
92 axillary nodes were pathologically examined by standard hematoxylin and eosin staining. Breast reconstruction
93 was simultaneously performed either by mobilization of the remnant mammary gland and by filling the lateral
94 thoracic fat tissue flap (LTF) or by filling an absorbent synthetic fiber [17].

95 Informed consent for the procedure was obtained from all the patients before surgery.

96 7 Results

97 We have performed 3D-CT LG on 160 patients, and the lymphoscintigraphy with 3D-CT LG on 32 patients.
98 3D-CT LG clearly showed the precise lymphatic flow from the tumor to SN (Fig ??). It showed periareolar
99 circular lymph ducts and complicated radial breast subcutaneous lymph ducts flow. They were connected to
100 make a network. It can show SN at only one minute after injection. By following up to 5 minutes, we can follow
101 the lymph ducts beyond SN into the second to the fifth node groups toward the venous angle with complex
102 plexus, observed in the surrounding anatomical architecture. The conventional lymphoscintigraphy shows only
103 information about the existence of nodes with the uptake of RI as hot spots (Fig ??a). We injected isotope 99m
104 technetium phytate 74MBq into the subcutane over the tumor and the periareola on the day before surgery. The
105 hot spots were observed, however, they cannot show the exact location of them on the anatomical structure and
106 the relations between lymph ducts and lymph nodes.

107 SPECT-CT can show the exact location of the hot spots on the axial view of the CT image, as showing in the
108 figure ??Fig 1b). They are always coincided with the axillary nodes. However, it cannot show the lymph ducts
109 and the relations between lymph ducts and nodes either. The number of hot spots was usually only one or two.
110 The average number was 1.2, which was less than the number 2.3 of SN found by 3D-CT LG.

111 We fused the DICOM data of SPECT with 3D-CT LG by using the image fusion software (Fig 3). The hot
112 spot can be coincided with enhanced SN observed on 3D-CT LG. However, not all of SNs had a hot spot. We
113 call SN with a hot spot as a hot node and SN without a hot spot as a cold node. We can recognize the location
114 of the cold nodes by using the relation to the hot nodes on the map of 3D-CT LG.

115 We experienced a profitable case to show this benefit (Fig 4a). The 3D-CT LG shows the lymph duct divides
116 into three branches and into three sentinel nodes. We call the blue stained node as a blue node and the unstained
117 node as a gray node in the dye staining method. SPECT-fused 3D-CT LG shows that the first one is hot and
118 blue, the second one is cold and blue, and the third one is cold and gray (Fig 3b). The metastasis was found
119 in the second one. We can detect the forth nodes, cold and gray. It was also metastasized. However, the other
120 axillary lymph nodes were not metastasized.

121 SN can be classified into four types under RI uptake and dye stainability. We summarized the number of the
122 cases with these four types of SNs in Table 2. We have examined 3D-CT LG with RI on 32 patients and with
123 SPECT on 20 patients. 25% of these patients had cold nodes. The metastasis was found on 6 patients. And on
124 2 patients the cold and blue nodes had metastases.

125 8 IV. Discussions

126 We previously reported that 3D-CT LG could show the precious lymphatic architecture of the breast and the
127 axilla, and its usefulness in SN biopsy [13,14,18]. It is not sure that there is only one node defined as SN. And
128 the lymph duct from the breast and the tumor to SN is not always single. However, the lymphoscintigraphy
129 shows an only single hot node without showing the other SNs. The other nodes adjacent to the hot node can
130 be sampled when they are stained with blue dye. On the other hand, SN distant from the hot node cannot be
131 sampled. 3D-CT LG shows the detailed relations of SNs and lymph ducts from the breast. It enables us to
132 sample this distant SN. The gray nodes adjacent to SN can also be recognized as SN or not, by 3D-CT LG.

133 During surgery, we have to project the mapping of 3D-CT LG on the patient body. We usually mark the
134 position of SN on the skin by oil pen at the laser pointer of CT. It is not sharp positioning because of the
135 distance from the skin to SN in the deep axilla. The anchoring needle is often used for the non-palpable mass
136 with calcifications in the mammary gland. It may be useful for SN marking, but it has a danger to harm
137 surrounding vessels in the axilla. The dye injection on the SN may be useful, but it is diluted and absorbed in
138 the tissue. It confuses the stained ducts and nodes, because we don't have enough colors of dye to be distinguished
139 between them. The ultrasonography may find the swelling nodes. It was reported to be synchronized to the
140 CT-LG data. It can show the location of SN, but it is disturbed by air and it cannot navigate us to find SN
141 during surgery. Therefore, the dye injection is needed with a guidance of ultrasound. RI detector gamma probe
142 can show the location of a hot node and navigate us to find a hot SN easily during surgery. Its location is
143 projected on the SN mapping of 3D-CT LG. We can sample not only these hot nodes but also the other cold SN
144 with relative node positions indicated by SPECTfused 3D-CT LG. The dye staining method also helps us to find
145 the hot SNs and the cold SNs.

146 We have performed endoscopic surgery for breast diseases, named as video-assisted breast surgery (VABS)
147 [19,20]. And we have reported about the advantage of the endoscopic SN biopsy [21]. It can remove SN by a
148 direct approach from the skin without detachment of the surrounding tissues. Therefore it becomes to be less
149 invasive than the conventional open biopsy. It needs only 1 cm long skin incision and leaves an inconspicuous
150 scar in the axilla. We can observe the dye stained ducts and nodes on the endoscopic view through the optical
151 trocar Visiport. We proceed into the fat tissue of the axilla bluntly and cut thin fascia sharply by the small
152 knife of Visiport. Even when it is difficult to find the dye because of the narrow field of vision, we can find the
153 hot nodes easily by the RI detector gamma probe. SPECT-fused 3D-CT LG helps us to anchor these hot SN in
154 order to navigate detecting all the other nodes on the mapping. We succeeded in the endoscopic SN biopsy on
155 all cases.

156 In Figure 4, the lymph duct from the tumor branched to three and into three different SNs. Only node #2 was
157 a cold-blue node and had metastasis. We might get into a danger of false negative study when SN biopsy was

9 V. CONCLUSION

performed only with RI method. SPECTfused 3D-CT LG presents the locational relations between hot nodes and cold nodes. SN biopsy with 3D-CT LG presents the relations between dye-stained blue nodes and unstained gray nodes. The numbers of the patients with these nodes are listed in Table 2. 25% of the patients had the cold nodes. Two patients with coldblue nodes had metastasis in their nodes. One patient with cold-gray nodes had metastasis. They may be a cause of false negative study, but they could evade such a danger by SPECT-fused 3D-CT LG.

The fluorescence study can show the precise lymph flow in mice, but in a human study the thick subcutaneous fat tissue disturbs the permeability of fluorescence to be visualized through the skin [22,23]. A new approach of lymphangiography has been reported by using MRI in mice [24,25]. It can show the precise lymphatic system in the anatomical architecture. It will be helpful for us to perform the selective axillary dissection and to preserve the arm lymph channel, like 3D-CT LG. However, it needs long time to exam, so it cannot follow the rapid lymph flow as one minute after injection like CT.

170 9 V. Conclusion

The endoscopic SN biopsy is aesthetic and less invasive, and SPECT-fused 3D-CT LG is valuable to ¹



12

Figure 1: Fig. 1 :Fig. 2 :




Figure 2: Fig. 3 :

171




Figure 3: Fig. 4 :




Figure 4: Endoscopic

1

Medical Age (y/o)	Tumor size (cm)	Mean Number	Patient Characteristics	RI + 3D-CT LG	Mean Range
Re- search			3D-CT LG		
Global Jour- nal of	Tis T1a / T1b / T1c T2 Lymph metastasis (N) Dis- tant metastasis (M) ER (+/-) PgR (+/-) HER2 (+/-)	Mean 1.9 Number 86 51 40 0 105 / 55 84 / 76 38 / 122	Range 26 -82 0.1 -10 %	Range 26 -82 0 29	57.4 26 -82
Total		160		12.5 3.1 / 6.2 / 56.3 21.9 18.8 0 81.2 59.4 9.4	32

[Note: 4 Volume XIV Issue III Version I]

Figure 5: Table 1 :

9 V. CONCLUSION

2

	metastasis		
	RI	Dye	Meta
#1	?	?	-
#2	-	?	?
#3	-	-	-
#4	-	-	?

RI: radioisotope, Meta: node metastasis

Figure 6: Table 2 :

3

Nodes	N	RI	Dye	?	?	-	?	-	-
3D-CT LG		32		26		3	6		2
SPECT 3D-CT LG		20		16		2	4		1

Figure 7: Table 3 :

1.1 Acknowledgements

172 We thank Professor Shin-ichiro Kumita (Department of Radiology, Nippon Medical School, Tokyo) for image
173 fusion analysis of SPECT.

175 [Minato et al. ()] '3-Dimensional computed tomography lymphography-guided medium. A clinical trial'. M
176 Minato , C Hirose , M Sasa . *J Comput Assist Tomogr* 2004. 28 p. .

177 [Kuehn et al. ()] 'A Concept for the Clinical Implementation of Sentinel Lymph Node Biopsy in Patients with
178 Breast Carcinoma with Special Regard to Quality Assurance'. T Kuehn , A Bembenek , T Decker . *Cancer*
179 2005. 103 p. .

180 [Koyama et al.] *A Dendrimer-Based Nanosized Contrast Agent Dual*, Y Koyama , V S Talanov , M Bernardo .

181 [Sykes et al. ()] 'A feasibility study for image guided radiotherapy using low dose, high speed, cone beam X-ray
182 volumetric imaging'. J R Sykes , A Amer , J Czajka , C J Moore . *Radiother Oncol* 2005. 77 p. .

183 [Kobayashi et al. ()] 'Comparison of Dendrimer-Based Macromolecular Labeled for Magnetic Resonance and
184 Optical Fluorescence Imaging to Localize the Sentinel Lymph Node in Mice'. H Kobayashi , S Kawamoto , P
185 L Choyke . *J Magn Reson Imaging* 2007. 25 p. .

186 [Yamashita and Shimizu ()] 'Endoscopic Video-Assisted Breast Surgery: Procedures and Short-Term Results'.
187 K Yamashita , K Shimizu . *J Nippon Med Sch* 2006. 73 p. .

188 [Yamashita and Shimizu ()] 'Evaluation of sentinel lymph node metastasis alone guided by threedimensional
189 computed tomographic lymphography in video-assisted breast surgery'. K Yamashita , K Shimizu .
190 10.1007/s00464-008-9809-z. *Surg Endosc* 2009. 23 p. .

191 [Hojo et al. ()] 'Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for
192 breast cancer'. T Hojo , T Nagao , M Kikuyama , S Akashi , T Kinoshita . DOI 10.1016/j.breast.2010.01.014.
193 *Breast* 2010.

194 [Yamashita et al. (ed.) ()] *From Local Invasion to Metastatic Cancer: Involvement of Distant Sites through the
195 Lymphovascular System*, K Yamashita , K Shimizu , 3d-Ct . Leong S (ed.) 2009. Springer, Totowa: Humana
196 Press. p. . (Lymphography for Mapping Metastatic Breast Sentinel Node and Axillary Nodes)

197 [Suga et al. ()] 'Interstitial CT lymphography-guided localization of breast sentinel lymph node: preliminary
198 results'. K Suga , N Ogasawara , M Okada . *Surgery* 2003. 133 p. .

199 [Borgstein et al. ()] 'Intradermal blue dye to identify sentinel lymph-node in breast cancer'. P J Borgstein , S
200 Meijer , R Pijpers . *Lancet* 1997. 384 p. .

201 [Giuliano et al. ()] 'Lymphatic mapping and sentinel lymphadenectomy for breast cancer'. A E Giuliano , D M
202 Kirgan , V Guether . *Ann Surg* 1994. 220 p. .

203 [Schrenk et al. ()] 'Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for
204 patients with breast carcinoma'. P Schrenk , R Rieger , A Shamiyah . *Cancer* 2000. 88 p. .

205 [Yamagata et al. ()] 'Partial mastectomy by the periareolar incision'. M Yamagata , T Takasugi , T Takayama .
206 *Geka Chiryo* 2002. 86 p. .

207 [Mariani et al. ()] 'Radioguided sentinel lymph node biopsy in breast cancer surgery'. G Mariani , L Moresco ,
208 G Viale . *J Nucl Med* 2001. 42 p. .

209 [Schwartz et al. ()] G F Schwartz , A E Giuliano , U Veronesi . *Proceedings of the consensus conference on the
210 role of sentinel lymph node biopsy in carcinoma of the breast*, (the consensus conference on the role of sentinel
211 lymph node biopsy in carcinoma of the breastPhiladelphia, Pennsylvania) April 19 to 22, 2001. 2002. 94 p. .

212 [Murawa et al. ()] 'Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence'. D
213 Murawa , C Hirche , S Dresel , M Hünerbein . *Br J Surg* 2009. 96 (11) p. .

214 [Tangoku et al. ()] 'Sentinel lymph node biopsy using computed tomographylymphography in patients with
215 breast cancer'. A Tangoku , S Yamamoto , K Suga . *Surgery* 2004. 135 p. .

216 [Veronesi et al. ()] 'Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative
217 lymph nodes'. U Veronesi , G Paganelli , V Galimberti . *Lancet* 1997. 349 p. .

218 [Krag et al. ()] 'Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a
219 gamma probe'. D N Krag , D L Weaver , J C Alex . *Surg Oncol* 1993. 2 (6) p. .

220 [Yamashita and Shimizu ()] 'Trans-axillary retromammary gland route approach of video-assisted breast surgery
221 can perform breast conserving surgery for cancers even in inner side of the breast'. K Yamashita , K Shimizu
222 . *Chin Med J* 2008. 121 p. .

223 [Yamashita and Shimizu ()] 'Transaxillary retromammary route approach of video-assisted breast surgery en-
224 ables the inner side breast cancer to be resected for breast-conserving surgery'. K Yamashita , K Shimizu .
225 *Am J Surg* 2008. 196 p. .

226 [Yamashita and Shimizu ()] 'Video-assisted Breast Surgery and Sentinel Lymph Node Biopsy guided by 3D-CT
227 lymphography'. K Yamashita , K Shimizu . 10.1007/s00464-007-9407-5. *Surg Endosc* 2008. 22 p. .

9 V. CONCLUSION

228 [Yamashita and Shimizu ()] 'Video-assisted breast surgery can sample the second and third sentinel nodes to
229 omit axillary node dissection for sentinelnode positive patients'. K Yamashita , K Shimizu . 10.1007/s00464-
230 009-0343-4. *Surg Endosc* 2009. 23 p. .

231 [Yamashita and Shimizu ()] 'Video-Assisted Breast Surgery: Reconstruction More than 33% Resected Breast'.
232 K Yamashita , K Shimizu . *J Nippon Med Sch* 2006. 73 p. .